Skip to content

Serotonin: all studies

Page 228 of 400: studies 2,271 to 2,280 of 3,999, newest first. Back to the serotonin overview

Research

The Role of the Dorsolateral Prefrontal Cortex in Ego Dissolution and Emotional Arousal During the Psychedelic State.

Human Brain Mapping April 1, 2025 Clayton R. Coleman, Kenneth Shinozuka, Robert Tromm et al. 4 citations

Lysergic acid diethylamide (LSD) is a classic serotonergic psychedelic that induces a profoundly altered conscious state. In conjunction with psychological support, it is currently being explored as a treatment for generalized anxiety disorder and depression. The dorsolateral prefrontal cortex (DLPFC) is a brain region that is known to be involved in mood regulation and disorders; hypofunction...

DOI: 10.1002/hbm.70209 (opens in new tab) Full text (opens in new tab) Psychedelics Consciousness Brain-imaging Altered-states

Clinical Research on Lysergic Acid Diethylamide (LSD) in Psychiatry and Neuroscience.

Pharmaceuticals March 29, 2025 Hossein Omidian, Alborz Omidian 5 citations

Lysergic acid diethylamide (LSD) is gaining renewed interest as a potential treatment for anxiety, depression, and alcohol use disorder, with clinical trials reporting significant symptom reductions and long-lasting effects. LSD modulates serotonin (5-HT2A) receptors, which, in turn, influence dysfunctional brain networks involved in emotional processing and cognition. It has also shown promise...

DOI: 10.3390/ph18040499 (opens in new tab) Full text (opens in new tab) LSD Clinical research Pharmacogenetics Serotonin receptors +8

Prophylactic Ketamine: Current Knowledge and Future Directions.

Biological Psychiatry March 28, 2025 Astrid M Cardona-Acosta, Lyonna F Parise, Carlos A. Bolaños-Guzmán et al. 2 citations

The prevalence of stress-induced disorders, including depression, anxiety, posttraumatic stress disorder, and postpartum depression, has been increasing, while current treatment approaches are limited. As a result, researchers are exploring alternative treatments that include ketamine as a prophylactic against these disorders. This review provides an overview of the current knowledge on the use...

DOI: 10.1016/j.biopsych.2025.03.015 (opens in new tab) Full text (opens in new tab) Neuroprotective drugs Prophylactic treatment Stress resilience Stress-induced psychiatric disorders +5

Motivation and retrospective appraisal of psychedelic study participation: a qualitative study in healthy volunteers.

Psychopharmacology March 26, 2025 Laura Ley, Matthias E. Liechti, Anna M Becker et al. 3 citations

Little is known about motives of healthy volunteers to participate in psychedelic trials and how they appraise their study experience retrospectively. This paper explored reasons why healthy people register for psychedelic trials, factors that they considered to contribute to either positive or negative study experiences, and under which circumstances they would seek a psychedelic experience...

Monoamine neurotransmitter-related gene-based genome-wide association study of low-dose ketamine in patients with treatment-resistant depression.

Journal of Psychopharmacology March 24, 2025 Chung-Feng Kao, Shih-Jen Tsai, Tung-Ping Su et al. 1 citation

Low-dose ketamine is an N-methyl-D-aspartate receptor antagonist that exerts an antidepressant effect on patients with treatment-resistant depression (TRD). This antidepressant effect may extend beyond the glutamatergic hypothesis. Nevertheless, the roles of genes encoding other monoamine neurotransmitters (i.e., serotonin and dopamine) in the neuromechanism of low-dose ketamine remain unknown....

DOI: 10.1177/02698811251326939 (opens in new tab) Full text (opens in new tab) Treatment-resistant depression Neurotransmitter studies Psychiatric genomics Antidepressant mechanisms +4

Pharmacological Monotherapy for Depressive Disorders: Current and Future-A Narrative Review.

Medicina (Kaunas, Lithuania) March 21, 2025 Keming Gao, Evrim Bayrak Oruc, Buket Koparal 9 citations

Objective: To narratively review currently available antidepressants and future potential antidepressants as monotherapy for the treatment of depressive disorders. Methods: Selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), dopamine reuptake inhibitor (bupropion), tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs) were...

DOI: 10.3390/medicina61040558 (opens in new tab) Full text (opens in new tab) N-methyl-d-aspartate receptor antagonists Anti-inflammatory agents Biomarker antidepressant therapy Depressive disorders +9

[Esketamine Alleviates Postoperative Depressive Symptoms in Frail Elderly Patients Undergoing Thoracoscopic Radical Resection of Lung Cancer: A Randomized Double-Blind Controlled Trial].

Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition March 20, 2025 Congli Zhang, Yan Yan, Junjie Ma et al. 1 citation

To investigate the effect of esketamine on postoperative depression in frail elderly patients undergoing thoracoscopic radical resection of lung cancer. A total of 88 frail elderly patients undergoing elective thoracoscopic radical resection of lung cancer were assigned randomly (using a randomization table) and in a double-blind way (blinding applies to both researchers and patients) to an...

DOI: 10.12182/20250360202 (opens in new tab) Full text (opens in new tab) Frail elderly patients Postoperative depressive state Thoracoscopy Esketamine: esketamine +8

Subdiaphragmatic vagotomy reduces hypothalamic oxytocin expression and blood levels after oral MDMA administration in male rats.

Progress in Neuro-Psychopharmacology and Biological Psychiatry March 20, 2025 Yong Yue, Xiayun Wan, Guilin Liu et al. 4 citations

3,4-Methylenedioxymethamphetamine (MDMA) is a widely recognized entactogen frequently used recreationally. It is known for its interaction with the serotonin and oxytocin systems, which underlie its entactogenic effects in humans. Recently, we demonstrated that the gut-brain axis, mediated by the subdiaphragmatic vagus nerve, contributes to MDMA-induced resilience enhancement in rodents. This...

DOI: 10.1016/j.pnpbp.2025.111260 (opens in new tab) Full text (opens in new tab) Gut-brain axis Oxytocin Paraventricular nucleus Supraoptic nucleus +4

N, N-dimethyltryptamine (DMT) in rodent brain: Concentrations, distribution, and recent pharmacological data.

Progress in Neuro-Psychopharmacology and Biological Psychiatry March 20, 2025 Steven A. Barker 3 citations

Renewed interest in the clinical use of psychedelic drugs acknowledges their therapeutic effectiveness. It has also provided a changing frame of reference for older psychedelic drug study data, especially regarding concentrations of N, N-dimethyltryptamine (DMT) reported in rodent brains and recent discoveries in DMT receptor interactions in rat brain neurons and select brain areas. The mode of...

Cross-Frequency Coupling as a Neural Substrate for Prediction Error Evaluation: A Laminar Neural Mass Modeling Approach

bioRxiv (Cold Spring Harbor Laboratory) March 19, 2025 Giulio Ruffini, Edmundo Lopez-Sola, Raul P. Aristides et al. 8 citations preprint

Abstract Predictive coding frameworks suggest that neural computations rely on hierarchical error minimization, where sensory signals are evaluated against internal model predictions. However, the neural implementation of this inference process remains unclear. We propose that cross-frequency coupling (CFC) furnishes a fundamental mechanism for this form of inference. We first demonstrate that...

DOI: 10.1101/2025.03.19.644090 (opens in new tab) Full text (opens in new tab) Laminar flow Artificial neural network Neural substrate Coupling piping +2